One day after the European Medicines Agency requested that three clinical trials of Elevidys be placed on hold after the ...

A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 ...

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety ...

A major trial of a promising gene therapy for Duchenne muscular dystrophy has fallen short, but researchers say the lessons learned could pave the way for better, more effective treatments.

Shares of Sarepta Therapeutics SRPT dropped more than 6% yesterday after the EMA placed a clinical hold on all studies ...

ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of ...

The determination comes after recruitment and dosing in certain trials were paused after a young patient died due to acute ...

Explore Solid Biosciences’ potential with promising SGT-003 trial results for DMD, strong financials, and market recovery ...

The best performers in the group are the Averill funds. Averill was down 2.9 percent in March but just 0.9 percent in the ...

April 4 (Reuters) - Sarepta Therapeutics (SRPT.O), opens new tab said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last ...

Shares of Sarepta Therapeutics SRPT dropped more than 6% yesterday after the EMA placed a clinical hold on all studies evaluating Elevidys, its one-shot gene therapy for Duchenne muscular ...